Inflammatory Profiles in Plasma and Cerebrospinal Fluid of Patients with Neurosarcoidosis

Overview

Journal J Neuroimmunol

Specialty Neurology

Date 2022 Apr 2

PMID 35366560

Authors

Keld-Erik Byg

Zsolt Illes

Tobias Sejbaek

Kate L Lambertsen

Torkell Ellingsen

Helle H Nielsen

Affiliations

Soon will be listed here.

Abstract

Methods: Cerebrospinal fluid (CSF) and plasma levels of 38 biomarkers from 20 neurosarcoidosis (NS) patients were compared to healthy controls (HC).

Results: In CSF, 25 biomarkers were significantly elevated compared to HC: IFNγ, TNFα, TNFβ, IL-2, IL-6, IL-10, IL-12B, IL-15, IL-16, CCL2, CCL3, CCL4, CCL11, CCL13, CCL17, CCL22, CCL26, CXCL8, CXCL10, TNFR2, VEGF-A, PIGF, SAA, VCAM1, and ICAM1. In plasma, 12 biomarkers were significantly elevated compared to HC: IFNγ, TNFα, CCL2, CCL3, CCL4, CCL17, CXCL10, VEGFR1, PIGF, SAA, VCAM1, and ICAM1.

Conclusion: NS patients have profoundly elevated cytokines, chemokines, vascular angiogenesis, and vascular injury biomarkers in CSF and plasma.

Citing Articles

Low-grade systemic inflammation, but not neuroinflammation, is associated with 12-month postoperative outcome after total hip arthroplasty in patients with painful osteoarthritis.

Blichfeldt-Eckhardt M, Varnum C, Lauridsen J, Rasmussen L, Mortensen W, Jensen H Bone Joint Res. 2024; 13(12):741-749.

PMID: 39637913 PMC: 11620800. DOI: 10.1302/2046-3758.1312.BJR-2024-0103.R1.

A serum B-lymphocyte activation signature is a key distinguishing feature of the immune response in sarcoidosis compared to tuberculosis.

Putera I, Schrijver B, Kolijn P, van Stigt A, Ten Berge J, IJspeert H Commun Biol. 2024; 7(1):1114.

PMID: 39256610 PMC: 11387424. DOI: 10.1038/s42003-024-06822-1.

Cerebrospinal Fluid Cytokine and Chemokine Profiles in Central Nervous System Sarcoidosis: Diagnostic and Immunopathologic Insights.

Mangioris G, Pittock S, Yang B, Fryer J, Harmsen W, Dubey D Ann Neurol. 2024; 96(4):704-714.

PMID: 39031103 PMC: 11568840. DOI: 10.1002/ana.27024.

Performance Measures and Plasma Biomarker Levels in Patients with Multiple Sclerosis after 14 Days of Fampridine Treatment: An Explorative Study.

Thorning M, Lambertsen K, Jensen H, Frich L, Madsen J, Olsen D Int J Mol Sci. 2024; 25(3).

PMID: 38338871 PMC: 10855557. DOI: 10.3390/ijms25031592.

Neurosarcoidosis.

Kidd D J Neurol. 2023; 271(2):1047-1055.

PMID: 37917231 DOI: 10.1007/s00415-023-12046-w.